<DOC>
	<DOCNO>NCT01005602</DOCNO>
	<brief_summary>Dosing method digoxin , drug use treat heart failure , update decade despite evidence recent year suggest blood level digoxin achieve traditional dosing practice may increase risk adverse event . We develop simple dose tool target low blood level digoxin associate improve outcome compare high blood level . The aim study determine simplify dose tool effective standard digoxin dose practice achieve low blood level also determine digoxin dosing may optimize incorporate patient ' genetic information believe influence drug 's property .</brief_summary>
	<brief_title>Digoxin Dosing Heart Failure : A Simplified Nomogram Versus Standard Care</brief_title>
	<detailed_description>Digoxin recommend adjunctive therapy patient leave ventricular dysfunction symptom heart failure despite treatment standard therapy . Recently , therapeutic range digoxin patient heart failure redefine narrow therapeutic window ( 0.5 - 0.9 ng/ml ) low serum level range associate improved survival whereas high serum level associate increased mortality . However , dose method update reflect newly define therapeutic range digoxin . We develop simplify dose nomogram digoxin patient heart failure design achieve serum digoxin concentration ( SDC ) within new therapeutic range use retrospective data . The long-term goal study prospectively validate ability digoxin dose nomogram achieve desire SDC provide clinician simplify tool optimize digoxin dose patient heart failure . Because digoxin substrate efflux pump p-glycoprotein ( pGP ) genetic polymorphism MDR1 gene ( know regulate pGP expression ) demonstrate conflict result pharmacokinetic profile digoxin , also characterize influence MDR1 functional gene variant may digoxin dose . This study include total 170 subject symptomatic heart failure treat digoxin , compare steady-state SDC prospective group patient dose accord nomogram historical control group dose digoxin derive standard dosing practice . We also conduct analysis genetic polymorphism MDR1 gene know affect digoxin pharmacokinetics . The primary objective study compare percentage patient group achieve steady-state SDC within desire range 0.5 - 0.9 ng/ml , characterize relationship genetic variability MDR1 gene digoxin dosing , update digoxin dose nomogram account clinical genetic variability show great influence digoxin dosing . The rationale study low dos digoxin recommend low SDC associate improved survival . Therefore , digoxin dose method must update reflect recommendation account genetic variability MDR1 gene effort improve clinical outcome minimize potential adverse event . To address issue , specific aim research : Aim 1 : Compare steady-state SDC observe use dose nomogram obtain use standard dosing practice . Aim 2 : Characterize relationship genetic variability MDR1 gene SDC observe use digoxin dose nomogram .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Age &gt; 21 year Diagnosis heart failure secondary leave ventricular dysfunction Receiving chronic digoxin therapy digoxin therapy initiate Pregnant Unstable renal function , define either rise serum creatinine &gt; 0.5mg/dl baseline decrease creatinine clearance 25 % within two four week study entry . Endstage renal disease require hemodialysis Concomitant therapy drug know interact digoxin ( e.g. , amiodarone , quinidine , verapamil , macrolide antibiotic )</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Digoxin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dosing</keyword>
	<keyword>Heart Failure</keyword>
</DOC>